X-trodes

Company Overview

Snapshot

Founded in July 2019 by Ziv Peremen and Prof. Yael Hanein, X-trodes operates with 11–50 employees. The company has raised $11.92 million across 4 funding rounds from 4 investors. In June 2023, X-trodes was awarded a grant from EIC Accelerator to advance its home sleep monitoring solution.

Business overview

X-trodes is a biotechnology company that specializes in remote physiological monitoring for clinical, home, and extreme environments. The company's core technology is a wireless, flexible, ultra-soft dry multi-electrode patch array system that measures and analyzes electrophysiological signals (EEG, EMG, EOG, ECG). This platform integrates innovative flexible sensors, a miniaturized low-noise Bluetooth amplifier, and cloud-based analytics, providing continuous, high-fidelity data acquisition and interpretation accessible via PC, tablet, or smartphone. X-trodes serves markets including medical and wellness monitoring, as well as high-stakes environments like aviation and defense with products such as PilotSense and HM-NEX.

Strategic signal

In September 2025, the Israeli Air Force began pioneering a new system to monitor pilots' physiological states in real-time using smart stickers that track vital signs. This initiative, which includes ground tests and planned integration into flight training, signals a significant validation of X-trodes' core technology for critical dual-use applications, demonstrating its potential to enhance safety and operational effectiveness in demanding environments beyond traditional healthcare.

Company Intelligence Q&A

What significant grant did X-trodes receive in 2023?

In June 2023, X-trodes was awarded a €5.2 million grant from the European Innovation Council Accelerator (EIC) to advance its home sleep monitoring solutions. This funding included a €2.5 million grant and an additional €2.7 million equity investment.

What product did X-trodes launch in December 2022?

In December 2022, X-trodes launched its first wearable solution for remote facial electromyography (fEMG) measurement. This technology provides capabilities for measuring facial muscle activity and assessing affective responses for medical, research, and consumer communities.

What was the outcome of the October 2021 seed funding round?

In October 2021, X-trodes completed a seed round that included investments from Japan-Israel High Tech Ventures and Welltech. This funding supported the development of wearable technology for advanced electrophysiological measurement and analytics.

What was the focus of the Tel Aviv University research commercialized by X-trodes?

In November 2021, researchers from Tel Aviv University developed a technology capable of detecting lies with 73% accuracy by measuring facial muscle movements using special electrodes. This technology, which X-trodes is commercializing, also has applications in home sleep monitoring and early detection of nerve diseases.

What was X-trodes' involvement with the Google for Startups Accelerator?

In January 2023, X-trodes graduated from the Google for Startups Accelerator program, indicating its participation in a corporate accelerator designed to support early-stage companies.